HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 289/3/R663    most recent 00275.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Hegele, R. A. Articles by Pollex, R. L. Search for Related Content PubMed PubMed Citation Articles by Hegele, R. A. Articles by Pollex, R. L.

CALL FOR PAPERS
Metabolic Syndrome

Genetic and physiological insights into the metabolic syndrome

Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute and University of Western Ontario, London, Ontario, Canada

Submitted 15 April 2005 ; accepted in final form 6 May 2005

The metabolic syndrome (MetS) is a common phenotype that is clinically defined by threshold values applied to measures of central obesity, dysglycemia, dyslipidemia, and/or elevated blood pressure, which must be present concurrently in any one of a variety of combinations. Insulin resistance, although not a defining component of the MetS, is nonetheless considered to be a core feature. MetS is important because it is rapidly growing in prevalence and is strongly related to the development of cardiovascular disease. To define etiology, pathogenesis and expression of MetS, we have studied patients, specifically Canadian families and communities. One example is familial partial lipodystrophy (FPLD), a rare monogenic form of insulin resistance caused by mutations in either LMNA, encoding nuclear lamin A/C (subtype FPLD2), or in PPARG, encoding peroxisomal proliferator-activated receptor- (subtype FPLD3). Because it evolves slowly and recapitulates key clinical and biochemical attributes, FPLD seems to be a useful monogenic model of MetS. A second example is the disparate MetS prevalence between two Canadian aboriginal groups that is mirrored by disparate prevalence of diabetes and cardiovascular disease. Careful phenotypic evaluation of such special cases of human MetS by using a wide range of diagnostic methods, an approach called "phenomics," may help uncover early presymptomatic disease biomarkers, which in turn might reveal new pathways and targets for interventions for MetS, diabetes, and atherosclerosis.

dyslipidemia; insulin resistance; cardiovascular disease; Canadian aboriginals; genetics

This article has been cited by other articles:

				B. C. Capell, F. S. Collins, and E. G. Nabel Mechanisms of Cardiovascular Disease in Accelerated Aging Syndromes Circ. Res., July 6, 2007; 101(1): 13 - 26. [Abstract] [Full Text] [PDF]

				J. Donkor, M. Sariahmetoglu, J. Dewald, D. N. Brindley, and K. Reue Three Mammalian Lipins Act as Phosphatidate Phosphatases with Distinct Tissue Expression Patterns J. Biol. Chem., February 9, 2007; 282(6): 3450 - 3457. [Abstract] [Full Text] [PDF]

				R. J. Schilder and J. H. Marden Metabolic syndrome and obesity in an insect PNAS, December 5, 2006; 103(49): 18805 - 18809. [Abstract] [Full Text] [PDF]

				P. B. Persson From clinical insights to new therapies Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R124 - R125. [Full Text] [PDF]